All News

Tochi Iroku-Malize, MD, discusses the ACIP's updated recommendations for immunization against COVID-19, influenza, and RSV.

The steroid-free cream was developed for long-term use and has been proven safe in an open-label extension study following successful phase 3 trials.

ICYMI: A quick look at 7 key drugs FDA-approved in the second quarter for conditions commonly seen in primary care.

Your daily dose of the clinical news you may have missed.

Long-term risk of death decreased by 26% and risk for vascular complications decreased by 40% in persons who remained diabetes-free for 4 years, according to new data.

The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.

Your daily dose of the clinical news you may have missed.

Continuous statin use among adults aged 75 years and older resulted in a mean relative risk reduction in CVD of 28% without heightened safety concerns, a new study found.

Following the statewide order in August 2022, emergency contraceptive fills at Massachusetts pharmacies increased by 32% compared with rates in other states.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

Your daily dose of the clinical news you may have missed.

Data from a study performed during the first season the shot was available expand on clinical trial evidence and support the safety of RSVpreF, authors wrote.

Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.

GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.

Your daily dose of the clinical news you may have missed.

Findings from a national survey also showed that Black respondents were most likely to believe they could not receive medications for OUD at a PCP.

Your daily dose of the clinical news you may have missed.

The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.